✦ LIBER ✦

Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: Overall survival analysis

✍ Scribed by Bradley J. Monk; Thomas J. Herzog; Stanley B. Kaye; Carolyn N. Krasner; Jan B. Vermorken; Franco M. Muggia; Eric Pujade-Lauraine; Youn C. Park; Trilok V. Parekh; Andres M. Poveda

Book ID: 116431108
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 709 KB
Volume: 48
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2012.04.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Patient-reported outcomes in relapsed ov

Patient-reported outcomes in relapsed ovarian cancer: Results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD Alone

✍ Carolyn N. Krasner; Andres Poveda; Thomas J. Herzog; Jan B. Vermorken; Stanley B 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 553 KB

8028 Safety analysis of trabectedin in c

8028 Safety analysis of trabectedin in combination with pegylated liposomal doxorubicin (PLD) vs PLD alone in ovarian cancer patients 65 years of age and older

✍ Vergote, I.; Vermorken, J.; Pujade-Lauraine, E.; Monk, B.; Lisyanskaya, A.; Rols 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

M284 TOXICITY WITH LONG-TERM PEGYLATED L

M284 TOXICITY WITH LONG-TERM PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) USE IN RECURRENT OVARIAN CANCER PATIENTS

✍ Arakawa, A.; Suzuki, R.; Kaminishizono, S.; Sato, R.; Kawano, A.; Sugo, Y.; Oi, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 61 KB

945 POSTER Efficacy of pegylated liposom

945 POSTER Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in patients with intermediate sensitive relapsing advanced ovarian cancer

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 141 KB

157 Overall survival advantage for pegyl

157 Overall survival advantage for pegylated liposomal doxorubicin compared to topotecan in recurrent epithelial ovarian cancer

✍ A. Gordon; A. Teitelbaum 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 162 KB

Trial in progress: A randomized double-b

Trial in progress: A randomized double-blind phase 3 trial comparing vintafolide+pegylated liposomal doxorubicin (PLD) versus PLD+placebo in patients with platinum-resistant ovarian cancer (PROCEED)

✍ Naumann, R.W.; Gilbert, L.; Habbe, A.; Ma, H.; Ghamande, S.; Vergote, I.B. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 58 KB